BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200310
DTEND;VALUE=DATE:20200313
DTSTAMP:20260515T064550
CREATED:20191218T094051Z
LAST-MODIFIED:20191218T094051Z
UID:23467-1583798400-1584057599@www.pharmajournalist.com
SUMMARY:Inborn Errors of Metabolism Drug Development
DESCRIPTION:Join over 80 inherited metabolic disease drug developers and KOLs to explore how the key challenges prohibiting accelerated drug development are being addressed. The inaugural Inborn Errors of Metabolism Drug Development Summit will provide a discursive platform to examine where pioneering gene therapy modalities intersect with current therapeutic options and explore how diseases can be better targeted in order to address the huge unmet medical need for rare metabolic diseases. \nWith scarce treatment options leaving inborn errors of metabolism a devastating\, unfilled and unmet medical need\, the opportunity for biopharma to do better and aggressively tap into a lucrative and life changing market of gene modalities is growing. For the first time\, the Inborn Errors of Metabolism Drug Development summit will look to examine how the experience within existing pharmacology for rare metabolic diseases can be leveraged with the drug development strategies of those pioneering gene modalities to improve efficacy\, safety and commercial viability. \nIncorporating insights from industry-leading speakers\, this conference will delve into the key patient access\, regulatory\, clinical and commercial hurdles that need to be overcome in order to address the unmet medical need of rare metabolic diseases and fulfil their full commercial potential. \nThis is your comprehensive guide to define your drug development path for 2020. Don’t miss out on your chance to network with industry leaders and be a part of the only enriched industry forum focused on accelerating the development of better effective treatments for inborn errors of metabolism. \nTo know more about Inborn Errors of Metabolism Drug Development please click here.
URL:https://www.pharmajournalist.com/event/inborn-errors-of-metabolism-drug-development/
LOCATION:Courtyard Boston Downtown/North Station\, 107 Beverly Street\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200312
DTEND;VALUE=DATE:20200314
DTSTAMP:20260515T064550
CREATED:20191031T101142Z
LAST-MODIFIED:20191031T104348Z
UID:23118-1583971200-1584143999@www.pharmajournalist.com
SUMMARY:4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress
DESCRIPTION:In the past decade\, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies\, cancer vaccines\, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction. \n \nOur 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 12th-13th March 2020 in London\, UK would address the challenges and future directions in IO research. The congress aims to bring academicians\, researchers and scientists from research institutes pharmaceutical\, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s\, Bispecific Antibodies\, Cellular Therapy and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies\, pre-clinical and translational immune-oncology developments\, updates in cellular and viral therapies\, vaccines development and personalized immunotherapy. Keynote presentations\, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions. \nKey Sessions: \n\nUpdates in development of monoclonal antibodies\, ADC’s and Bispecific Ab’s\nImmune Checkpoint Inhibitors and Combinations\nPreclinical and Translational Immuno-Oncology Developments (Preclinical models for Immunecheckpoint modulators)\nBiomarkers and Cancer Vaccines\nCAR-T cell therapy\, T Cell Therapy\nTumor microenvironment\nOncolytic Viruses\nMicrobiome in Cancer Immunotherapy\n\nTo learn more about 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress click here \n 
URL:https://www.pharmajournalist.com/event/4th-annual-marketsandmarkets-next-gen-immuno-oncology-congress/
LOCATION:ILEC Conference Center and IBIS London Earls Court\, 47 Lillie Road\, London\, SW6 1UD
ORGANIZER;CN="MarketsandMarkets Research Private Ltd.":MAILTO:shardul.oza@marketsandmarkets.com
END:VEVENT
END:VCALENDAR